SEARCH

SEARCH BY CITATION

References

  • 1
    Davies C, Forrester SD. Pleural effusion in cats: 82 cases (1987 to 1995). J Small Anim Pract 1996; 37(5):217224.
  • 2
    Hirschberger J, DeNicola DB, Hermanns W, et al. Sensitivity and specificity of cytologic evaluation in the diagnosis of neoplasia in body fluids from dogs and cats. Vet Clin Pathol 1999; 28(4):142146.
  • 3
    Zoia A, Slater LA, Heller J, et al. A new approach to pleural effusion in cats: markers for distinguishing transudates from exudates. J Feline Med Surg 2009; 11(10):847855.
  • 4
    Suter PF. Pleural abnormalities. In: Suter PF, Lord PF. eds. Thoracic Radiography, 1st ed. Wettswil, Switzerland: Peter F. Suter; 1984, pp. 683734.
  • 5
    Connolly DJ, Magalhaes RJS, Syme HM, et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008; 22(1):96105.
  • 6
    Connolly DJ, Soares Magalhaes RJ, Fuentes VL, et al. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009; 11 (Suppl 1):S4150.
  • 7
    Fox P, Rush J, Reynolds C, et al. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats. J Vet Intern Med 2011; 25(5):10101016.
  • 8
    Fox PR, Oyama MA, Reynolds C, et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009; 11(Suppl 1):S5161.
  • 9
    Hsu A, Kittleson MD, Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009; 11(Suppl 1):S6370.
  • 10
    Lalor SM, Connolly DJ, Elliott J, Syme HM. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol 2009; 11 Suppl 1:S7179.
  • 11
    Singh MK, Cocchiaro MF, Kittleson MD. NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats. J Feline Med Surg 2010; 12(12):942947.
  • 12
    Tominaga Y, Miyagawa Y, Toda N, et al. The diagnostic significance of the plasma N-terminal pro-B-type natriuretic peptide concentration in asymptomatic cats with cardiac enlargement. J Vet Med Sci 2011; 73(8):971975.
  • 13
    Wess G, Daisenberger P, Mahling M, et al. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats. Vet Clin Pathol 2011; 40(2):237244.
  • 14
    van Kimmenade RRJ, Januzzi JL. The evolution of the natriuretic peptides—current applications in human and animal medicine. J Vet Cardiol 2009; 11(Suppl 1):S921.
  • 15
    Gegenhuber A, Mueller T, Dieplinger B, et al. Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest 2005; 128(2):10031009.
  • 16
    Han CH, Choi JE, Chung JH. Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions. Intern Med 2008; 47(19):16691674.
  • 17
    Kolditz M, Halank M, Schiemanck CS, et al. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J 2006; 28(1):14450.
  • 18
    Liao H, Na MJ, Dikensoy O, et al. Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases. Respirology 2008; 13(1):5357.
  • 19
    Long AC, O'Neal HR, Peng S, et al. Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels. Chest 2010; 137(6):13691374.
  • 20
    Marinho FC, Vargas FS, Fabri J, et al. Clinical usefulness of B-type natriuretic peptide in the diagnosis of pleural effusions due to heart failure. Respirology 2011; 16(3):495499.
  • 21
    Porcel JM, Chorda J, Cao G, et al. Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient for the identification of cardiac effusions misclassified by Light's criteria. Respirology 2007; 12(5):654659.
  • 22
    Porcel JM, Martínez-Alonso M, Cao G, et al. Biomarkers of heart failure in pleural fluid. Chest 2009; 136(3):671677.
  • 23
    Porcel JM, Vives M, Cao G, et al. Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 2004; 116(6):417420.
  • 24
    Tomcsányi J, Nagy E, Somlói M, et al. NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates. Eur J Heart Fail 2004; 6(6):753756.
  • 25
    Valdés L, José ES, Pose A, et al. Diagnostic value of N-terminal pro-brain natriuretic peptide in pleural effusions of cardiac origin. Arch Bronconeumol 2011; 47(5):246251.
  • 26
    Rizzi TE, Cowell RL, Tyler RD, et al. Effusions: abdominal, thoracic and pericardial. In: Cowell RL, Meinkoth JH, Tyler RD, DeNicola DB. eds. Diagnostic Cytology and Hematology of the Dog and Cat. St. Louis, MO: Mosby Inc.; 2007, pp. 235255.
  • 27
    MacDonald K. Myocardial disease: feline. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed. St. Louis, MO: Saunders; 2010, pp. 13281341.
  • 28
    Taube A. Sensitivity, specificity and predictive values: a graphical approach. Stat Med; 5(6):585591.
  • 29
    Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2008; 49(1):2632.
  • 30
    Fine DM, DeClue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008; 232(11):16741679.
  • 31
    Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008; 232(10):14961503.
  • 32
    Oyama MA, Rush JE, Rozanski EA, et al. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009; 235(11):13191325.
  • 33
    Pimenta J, Paulo C, Gomes A, et al. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010; 30(7):10591066.
  • 34
    Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129(5):13491366.
  • 35
    Meyer B, Huelsmann M, Wexberg P, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007; 35(10):22682273.
  • 36
    Hassdenteufel E, Kresken JG, Henrich E, et al. NT proBNP as a diagnostic marker in dogs with dyspnea and in asymptomatic dogs with heart murmur. Tierärztl Prax K (Tierärztliche Praxis Kleintiere) 2012; 40(3):171179.
  • 37
    DeFrancesco TC, Rush JE, Rozanski EA, et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007; 21(2):243250.
  • 38
    Kellihan HB, Mackie BA, Stepien RL. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension. J Vet Cardiol 2011; 13(3):171182.
  • 39
    Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005; 45(11):19001902.
  • 40
    Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9):797805.
  • 41
    Schober KE, Hart TM, Stern JA, et al. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011; 239(4):468479.
  • 42
    Swift S, Dukes-McEwan J, Fonfara S, et al. Aetiology and outcome in 90 cats presenting with dyspnoea in a referral population. J Small Anim Pract 2009; 50(9):466473.
  • 43
    Porcel JM. Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure. Curr Opin Pulm Med 2011; 17(4):215219.